DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the NMIBC Pipeline? @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight

Key Takeaways from the NMIBC Pipeline Report

• On July 06, 2026- Merck Sharp & Dohme LLC initiated a phase 1/2 study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
• On July 02, 2026- Astellas Pharma Global Development Inc. announced a phase 3 study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
• On July 01, 2026- CG Oncology Inc. conducted a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
• On July 01, 2026- Ferring Pharmaceuticals highlighted a phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
• DelveInsight’s Non Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Non Muscle Invasive Bladder Cancer treatment.
• The leading Non Muscle Invasive Bladder Cancer Companies such as CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
• Promising Non Muscle Invasive Bladder Cancer Therapies such as PF-06801591, Bacillus Calmette-Guerin, CG0070, Gemcitabine, APL-1202 treatment, Durvalumab, eRapa, Epirubicin Hydrochloride, Cabazitaxel, Gemcitabine, Cisplatin and others.

Want to know which companies are leading innovation in Non-Muscle Invasive Bladder Cancer? @ NMIBC Clinical Trials Assessment

The NMIBC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The NMIBC Pipeline Report also highlights the unmet needs with respect to the development of Non Muscle Invasive Bladder Cancer.

NMIBC Overview

Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer in which the tumor remains confined to the inner lining of the bladder and does not invade the muscular wall. NMIBC includes stages Ta, T1, and carcinoma in situ (CIS), and is characterized by abnormal growth of urothelial cells within the bladder mucosa. Although the disease is generally considered less aggressive than muscle-invasive bladder cancer, it has a strong tendency for recurrence and progression in some patients, making continuous monitoring important.

Non Muscle Invasive Bladder Cancer Emerging Drugs Profile

• Cretostimogene grenadenorepvec: CG Oncology

Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate in and destroy bladder cancer cells while also stimulating anti-tumor immune responses. The therapy is engineered with an E2F-1 promoter to target tumor cells with altered Rb-E2F pathways and includes the GM-CSF gene to enhance immune activation. Viral replication causes tumor cell lysis and releases tumor antigens and GM-CSF, helping trigger a sustained immune response against bladder cancer. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

• FGFR3 (TYRA-300): Tyra Biosciences, Inc.

FGFR3 (TYRA-300) is Tyra Biosciences’ lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational oral FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia, including achondroplasia and hypochondroplasia. In oncology, TYRA-300 is being evaluated in metastatic urothelial cancer (mUC) and intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

• MK-3120: Merck & Co., Inc.

MK-3120 is an investigational therapy for bladder cancer, including non-muscle invasive bladder cancer (NMIBC). MK-3120 is a Nectin-4-targeting antibody-drug conjugate (ADC) that carries a topoisomerase I (topo I) inhibitor payload. The drug is designed to specifically bind to Nectin-4, a protein highly expressed on bladder cancer cells. After binding to the tumor cell, the ADC is internalized and releases its topo I inhibitor payload inside the cancer cell, leading to DNA damage, disruption of DNA replication, and ultimately cancer cell death. By selectively targeting Nectin-4–expressing tumor cells, MK-3120 aims to deliver potent anti-cancer activity while limiting exposure to normal tissues. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

• AU-011: Aura Biosciences

AU-011 is a first-in-class virus-like drug conjugate (VDC) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The therapy is designed to selectively target and destroy cancer cells while sparing healthy tissue. AU-011 binds to heparan sulfate proteoglycans (HSPGs), which are overexpressed on bladder cancer cells, allowing selective tumor targeting. After binding to the tumor cells, the drug is activated by light, leading to rapid disruption of the cancer cell membrane and acute tumor cell death. This process also promotes immunogenic cell death, releasing tumor antigens that may stimulate a systemic anti-tumor immune response and generate longer-term immunity against the cancer. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.

NMIBC Market Drivers

• Increasing NMIBC Prevalence
• Advancements in Bladder Cancer Treatment

NMIBC Market Barriers

• Increasing use of Biologics and Targeted Therapies
• High Cost associated with the disease

The Non Muscle Invasive Bladder Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.
• Non Muscle Invasive Bladder Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.

If you’re tracking ongoing NMIBC clinical trials, this press release is a must-read @ NMIBC Treatment Drugs

Non Muscle Invasive Bladder Cancer Companies

CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the NMIBC Pipeline Report covers it all @ NMIBC Market Drivers and Barriers, and Future Perspectives

Scope of the NMIBC Pipeline Report

• Coverage- Global
• NMIBC Companies- CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
• NMIBC Therapies- PF-06801591, Bacillus Calmette-Guerin, CG0070, Gemcitabine, APL-1202 treatment, Durvalumab, eRapa, Epirubicin Hydrochloride, Cabazitaxel, Gemcitabine, Cisplatin and others.
• NMIBC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• NMIBC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the NMIBC treatment landscape in this detailed analysis @ NMIBC Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Non Muscle Invasive Bladder Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Cretostimogene grenadenorepvec: CG Oncology
9. Mid Stage Products (Phase II)
10. TYRA-300: Tyra Biosciences, Inc
11. Early Stage Products (Phase I)
12. UGN-301: UroGen Pharma Ltd.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Non Muscle Invasive Bladder Cancer Key Companies
17. Non Muscle Invasive Bladder Cancer Key Products
18. Non Muscle Invasive Bladder Cancer- Unmet Needs
19. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
20. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
21. Non Muscle Invasive Bladder Cancer Analyst Views
22. Non Muscle Invasive Bladder Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight